Clinical trial
Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone…
NCT00022516 · ETOP IBCSG Partners Foundation, Other · Completed
Key facts
| NCT number | NCT00022516 |
|---|---|
| Title | Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer |
| Official title | Low-dose Cytotoxics as "Anti-angiogenesis Treatment" Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer |
| Acronym | 22-00 |
| Lead sponsor | ETOP IBCSG Partners Foundation, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Cyclophosphamide, Methotrexate |
| Enrollment | 1,086 |
| Start date | Nov 1, 2000 |
| Primary completion | Jan 1, 2015 |
| Completion | Aug 1, 2016 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 16, 2016 |
| Countries | Australia, Belgium, Brazil, Chile, Hungary, Italy, Nigeria, Peru, Romania, South Africa, Switzerland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: